In biotech, revolutions don’t always explode out of billion-dollar campuses. Sometimes they take root in Medford, Massachusetts, where a women-owned public benefit corporation is quietly reshaping the economics of protein manufacturing. Sunflower Therapeutics, founded in 2018 by Kerry R. Love, PhD, Kathryn Golden, MEng, MBA, and J. Christopher Love, PhD, isn’t chasing the now; it’s engineering the infrastructure that makes vaccines, therapeutics, and alternative proteins not just possible but accessible worldwide.
Their latest move: an SBIR grant of up to $2.36 million from the National Institute of Allergy and Infectious Diseases, part of NIH. The structure is milestone-based, $300,000 to start, more as they deliver. The goal is bold but focused: an automated continuous cell disruption platform designed to scale virus-like particle vaccines. It’s a direct shot at one of the bottlenecks that keeps lifesaving doses from reaching markets that need them most.
But don’t mistake this as Sunflower’s first windfall. The company has secured over $43 million across grants, contracts, and investments. Clear Current Capital led a $3 million SAFE in December 2024, SK bioscience followed with $2 million in July, and earlier rounds saw multimillion-dollar support from the Bill & Melinda Gates Foundation and DARPA. Add profitability since 2019, and the message is clear: Sunflower isn’t burning cash to chase a dream; it’s already running a business with traction.
The execution is just as sharp inside their 9,500-square-foot Medford facility. Twenty-two employees, more than 80 percent scientists and engineers, over half women, are powering a platform that has already delivered its first Daisy Petal Perfusion Bioreactor System. Yields five to ten times higher than fed-batch methods, paired with Dahlia Petal for larger runs, and supported by HelianthOS, Nursery, and Harvest software, this isn’t academic tinkering. It’s modular, automated, and deployable from Boston to Bangalore.
Eleven patents filed, commercial distribution spanning Asia, Europe, and North America, and recognition like “Lifescience Manufacturing Solution of the Year” prove the impact isn’t just theoretical. With partners like PharmNXT Biotech in India and Alflow Scandinavia in Europe, Sunflower is proving decentralized biomanufacturing can be a commercial reality.
The leadership lineup matches the ambition. Kerry R. Love drives vision as CEO and President, Kathryn Golden anchors strategy, and J. Christopher Love provides academic and entrepreneurial firepower as Chairman. The team extends with Laura E. Crowell, PhD, leading R&D, Alexandra Bonnyman steering engineering operations, Dave Bianchi directing commercial ops, Tom Heer running finance, and Jodie Crowley overseeing people and operations. Scientists like Mary Kate Tracey and Akshada Shinde make the innovation tangible.
Here’s the real lesson. By shrinking the footprint of advanced bioprocessing and aligning it with market realities in health and food, Sunflower Therapeutics is making scale a choice, not a barrier. This isn’t about raising rounds for headlines, it’s about raising access for billions.
